Brief: VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results Of Phase 2 Study

VBI Vaccines

06/09/2023 13:13

Sept 6 (Reuters) - VBI Vaccines Inc  VBIV.O :
    * VBI VACCINES PARTNER BRII BIOSCIENCES ANNOUNCES TOPLINE
INTERIM
RESULTS OF PHASE 2 STUDY EVALUATING BRII-179 (VBI-2601) IN
COMBINATION WITH PEG-IFNΑ FOR THE TREATMENT OF CHRONIC HEPATITIS
B
    * VBI VACCINES INC: BRII-179 AS AN ADD-ON THERAPY TO
STANDARD OF
CARE PEG-IFNΑ INCREASES HBSAG LOSS RATE AT END OF TREATMENT AND
12 WEEKS FOLLOW UP
    * VBI: SIGNIFICANTLY INCREASED SEROCONVERSION RATE IS
STRONGLY
ASSOCIATED WITH BRII-179 TREATMENT AND CORRELATES WITH INCREASED
RATE OF HBSAG LOSS
    * VBI VACCINES INC: SAFETY FINDINGS ARE SIMILAR TO THOSE OF
PEG-IFNΑ AND BRII-179 (VBI-2601) AS PREVIOUSLY REPORTED

Source text for Eikon:  ID:nBw1JzxQVa 
Further company coverage:  VBIV.O 

 ((Reuters.briefs@thomsonreuters.com;))